ORGANIGRAM GLOBAL INC.

Organigram Global Inc. announced an accelerated integration of Sanity Group and a unified global operating model, aiming to streamline operations and enhance profitability. The company anticipates annualized run-rate cost savings of $8 million to $10 million in Fiscal 2027, with a phased impact of $5 million to $6 million in the same fiscal year. This restructuring includes consolidating global functions, optimizing Canadian manufacturing, and focusing investment on three core brands while discontinuing others. These actions are expected to reduce manufacturing complexity, improve gross margins, and support disciplined global growth.

Organigram Global Inc. reported a significant increase in net income to $105.5 million for Q3 Fiscal 2026, compared to a net loss of $6.3 million in the prior year, primarily driven by a $105.8 million fair value gain on Preferred Shares. Net revenue grew 49% to $105.8 million, largely due to the acquisition of Sanity Group in April 2026, which boosted international medical sales. The company also achieved a 136% increase in Adjusted EBITDA to $13.4 million and maintained its #1 market share in Canadian recreational cannabis. However, Organigram is pausing its US hemp-derived THC business due to upcoming regulatory changes.

Organigram Global Inc. announced it will report its third quarter fiscal 2026 earnings results on Tuesday, August 11, 2026, before market open. The company will host a conference call on the same day at 8:00 am Eastern Time to discuss the results. Details for registration and webcast access have been provided, with a replay available for 90 days.

Organigram Global Inc. provided a business update highlighting the initial operating performance of its acquired Sanity Group and continued strength in its Canadian market share. Sanity Group has maintained approximately 10% market share in Germany and performed in line with revenue expectations since its acquisition in April 2026. In Canada, Organigram continues to lead in flower and vape categories, with overall recreational cannabis market share improving sequentially in June. The company also announced it expects to report its Q3 Fiscal 2026 results, including Sanity's financials, around August 11, 2026, and will host a Digital Investor Session in late September 2026.

Organigram Global reported a net loss of $0.92 million for Q2 Fiscal 2026, a significant decrease from a net income of $42.46 million in Q2 Fiscal 2025, with net revenue declining 9% to $59.79 million. The company recognized a $5.8 million impairment charge due to new US regulatory restrictions affecting hemp-derived products. Subsequent to the quarter, Organigram closed the acquisition of Sanity Group for €107.3 million and updated its Fiscal 2026 guidance, projecting net revenue to exceed $350 million and Adjusted EBITDA to surpass Fiscal 2025 performance.

Organigram Global Inc. announced it will report its second quarter fiscal 2026 results, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The company will host a conference call at 8:00 am Eastern Time on the same day to discuss the results. Details for registration and webcast access have been provided, with a replay available online for 90 days.